Allergan, Inc.

Gilead Sciences, Inc.

Selcia Limited

Hans G Fliri

Simon Neil Pettit

June Chen

Richard L Mackman

Linos Lazarides

Victoria Alexandra Steadman

Karine G Poullennec

Andrew John Keats

Todd Appleby

Jonathan Sanvoisin

Gregory M Watt

David Frederick Woodward

Jenny W Wang

Jose L Martos

Clive L Cornell

Andrew J Keats

Victoria A Steadman

The present specification discloses cannabinoid-2 agonists, compositions comprising such cannabinoid-2 agonists, and methods of treating an individual suffering from a disease by administering compositions comprising such cannabinoid-2 agonists.

Cannabinoid-2 agonists

The present specification discloses cannabinoid-2 agonists, compositions comprising such cannabinoid-2 agonists, and methods of treating an individual suffering from a disease by administering compositions comprising such cannabinoid-2 agonists. (Formula I and III) 

Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.

Macrocyclic inhibitors of flaviviridae viruses

The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I wherein Y, Q, Z, R, Rand Rare as defined in the specification. The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound of formula I.

Abnormal cannabidiols as agents for lowering intraocular pressure

The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula I wherein Y, Q, Z, R, Rand Rare as defined in the specification. The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound.

The present invention provides prostamide receptor antagonist compounds that may be represented by the general formula I wherein A, R, R, R, Rand Rare as defined in the specification.

Prostamide receptor antagonists

Abnormal Cannabidiols as agents for lowering intraocular pressure

Growing community of inventors

Essex, United Kingdom

Hans G Fliri